BI
FDMT icon

BVF Inc’s 4D Molecular Therapeutics FDMT Stock Holding History

BVF Inc’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$38.3M Hold
2,879,289
– – 0.98% 26
2026
Q1 		$26.8M Sell
2,879,289
-1,750,000
-38% -$15.2M 0.85% 28
2025
Q4 		$34.7M Hold
4,629,289
– – 1.17% 26
2025
Q3 		$40.2M Hold
4,629,289
– – 1.63% 22
2025
Q2 		$17.2M Buy
4,629,289
+68,000
+1% +$239K 0.61% 25
2025
Q1 		$14.7M Buy
4,561,289
+1,890,647
+71% +$8.91M 0.6% 28
2024
Q4 		$14.9M Sell
2,670,642
-4,712,000
-64% -$37M 0.5% 32
2024
Q3 		$79.8M Buy
7,382,642
+3,460,229
+88% +$57.4M 2.33% 12
2024
Q2 		$82.3M Hold
3,922,413
– – 2.31% 13
2024
Q1 		$125M Sell
3,922,413
-85,000
-2% -$2.17M 3.44% 4
2023
Q4 		$81.2M Hold
4,007,413
– – 2.03% 10
2023
Q3 		$51M Hold
4,007,413
– – 1.38% 20
2023
Q2 		$72.4M Hold
4,007,413
– – 2.02% 13
2023
Q1 		$68.9M Hold
4,007,413
– – 2.52% 13
2022
Q4 		$89M Hold
4,007,413
– – 3.76% 6
2022
Q3 		$32.2M Hold
4,007,413
– – 1.33% 27
2022
Q2 		$28M Buy
4,007,413
+1,342,892
+50% +$13.1M 1.35% 25
2022
Q1 		$40.3M Buy
2,664,521
+658,659
+33% +$10.3M 1.61% 22
2021
Q4 		$44M Hold
2,005,862
– – 1.6% 20
2021
Q3 		$54.1M Hold
2,005,862
– – 2.11% 15
2021
Q2 		$48.3M Buy
2,005,862
+974,792
+95% +$29.8M 1.81% 14
2021
Q1 		$44.7M Sell
1,031,070
-75,000
-7% -$3.32M 1.68% 20
2020
Q4 		$45.8M Buy
+1,106,070
New +$45.7M 1.8% 17

Other funds holding FDMT

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BVF Inc's FDMT Position: Q2 2026 in Review

BVF Inc held its 4D Molecular Therapeutics (FDMT) position steady in Q2 2026 at 2,879,289 shares worth $38.3M. The position accounts for 0.98% of the portfolio, ranked #26.

BVF Inc first reported a position in FDMT in Q4 2020 and has held it in 23 quarters since. The position peaked at $125M in Q1 2024. 158 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

  • BVF Inc held 2,879,289 shares of 4D Molecular Therapeutics worth $38.3M as of Q2 2026.
  • BVF Inc left its 4D Molecular Therapeutics share count unchanged in Q2 2026.
  • 4D Molecular Therapeutics made up 0.98% of BVF Inc's portfolio in Q2 2026, its #26 holding.
  • BVF Inc first reported a position in 4D Molecular Therapeutics in Q4 2020 and has held it in 23 quarters since.
  • BVF Inc's 4D Molecular Therapeutics position peaked at $125M in Q1 2024.
  • 158 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on BVF Inc's 13F filing for Q2 2026, filed 14 Aug 2026.